Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J., Herndon, J. E., … Reardon, D. A. (2010). Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. Journal of Clinical Oncology, 28(15_suppl), 2055–2055. https://doi.org/10.1200/jco.2010.28.15_suppl.2055

Sathornsumetee, S., A. Desjardins, J. J. Vredenburgh, R. E. McLendon, J. Marcello, J. E. Herndon, J. Norfleet, S. Gururangan, H. S. Friedman, and D. A. Reardon. “Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2055–2055. https://doi.org/10.1200/jco.2010.28.15_suppl.2055.

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, et al. Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):2055–2055.

Sathornsumetee, S., et al. “Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 2055–2055. Crossref, doi:10.1200/jco.2010.28.15_suppl.2055.

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Norfleet J, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):2055–2055.